MOZOBIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mozobil, and when can generic versions of Mozobil launch?
Mozobil is a drug marketed by Genzyme and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-two patent family members in twenty-seven countries.
The generic ingredient in MOZOBIL is plerixafor. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the plerixafor profile page.
DrugPatentWatch® Generic Entry Outlook for Mozobil
Mozobil was eligible for patent challenges on December 15, 2012.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be July 22, 2023. This may change due to patent challenges or generic licensing.
There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There is one tentative approval for the generic drug (plerixafor), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Summary for MOZOBIL
International Patents: | 52 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 101 |
Clinical Trials: | 84 |
Patent Applications: | 3,873 |
Drug Prices: | Drug price information for MOZOBIL |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MOZOBIL |
What excipients (inactive ingredients) are in MOZOBIL? | MOZOBIL excipients list |
DailyMed Link: | MOZOBIL at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for MOZOBIL
Generic Entry Date for MOZOBIL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MOZOBIL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Albert Einstein College of Medicine | Phase 1 |
Doris Duke Charitable Foundation | Phase 2 |
David Loeb | Phase 1 |
Pharmacology for MOZOBIL
Drug Class | Hematopoietic Stem Cell Mobilizer |
Physiological Effect | Increased Hematopoietic Stem Cell Mobilization |
Anatomical Therapeutic Chemical (ATC) Classes for MOZOBIL
Paragraph IV (Patent) Challenges for MOZOBIL
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MOZOBIL | Injection | plerixafor | 24 mg/1.2 mL vials (20 mg/mL) | 022311 | 3 | 2012-12-17 |
US Patents and Regulatory Information for MOZOBIL
MOZOBIL is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of MOZOBIL is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting MOZOBIL
Methods to mobilize progenitor/stem cells
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
Methods to mobilize progenitor/stem cells
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MOZOBIL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | See Plans and Pricing | See Plans and Pricing |
Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MOZOBIL
See the table below for patents covering MOZOBIL around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Czech Republic | 9401188 | See Plans and Pricing | |
New Zealand | 246179 | LINKED CYCLIC POLYAMINES WITH ACTIVITY AGAINST HIV; PHARMACEUTICAL COMPOSITIONS | See Plans and Pricing |
Portugal | 619813 | See Plans and Pricing | |
Norway | 344632 | See Plans and Pricing | |
European Patent Office | 1223166 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MOZOBIL
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1411918 | C20120014 00064 | Estonia | See Plans and Pricing | PRODUCT NAME: MOZOBIL - PLERIXAFOR;REG NO/DATE: C(2009)6238 31.07.2009 |
2371361 | 2019/055 | Ireland | See Plans and Pricing | PRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; NAT REGISTRATION NO/DATE: EU/1/09/537/001 20090804; FIRST REGISTRATION NO/DATE: EU/1/09/537/001 04/08/2009 (14/10/2020) |
1411918 | 215 5011-2012 | Slovakia | See Plans and Pricing | PRODUCT NAME: PLERIXAFOR; REGISTRATION NO/DATE: EU/1/09/537/001 20090804 |
2371361 | CA 2019 00044 | Denmark | See Plans and Pricing | PRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; REG. NO/DATE: EU/1/09/527/001 20090731 |
1411918 | PA2012011,C1411918 | Lithuania | See Plans and Pricing | PRODUCT NAME: PLERIXAFORUM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |